Clinical Trial Update: A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of hepatic impairment on the pharmacokinetics and tolerability of eliglustat tartrate in Gaucher disease; the trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Eliglustat Tartrate (Eliglustat tartrate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Gaucher Disease | Phase 1 | Status: COMPLETED